Drug Profile
FS 118
Alternative Names: FS-118; LAG-3/PD-L1 Bispecific AntibodyLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator f-star
- Developer F-star Therapeutics; Merck KGaA
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diffuse large B cell lymphoma; Head and neck cancer; Non-small cell lung cancer
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Haematological-malignancies(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma